GLP-1 derivative and preparation thereof absorbable via...

Details GLP-1 derivative and preparation thereof absorbable via... GLP-1 derivative and preparation thereof absorbable via...

2007-11-06

2007-11-06

Gupta, Anish (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S866000, C530S308000, C530S324000

Reexamination Certificate

active

10530125

ABSTRACT:
A GLP-1 derivative is provided including an amino acid sequence of GLP-1 (7-35) having deletion, substitution and/or addition of one or more amino acids and having Waa-(Xaa)n-Yaa (in which Waa is Arg or Lys, Xaa is Arg or Lys, n is an integer of 0 to 14, and Yaa is Arg, Arg-NH2, Lys, Lys-NH2or Hse) added to the C-terminus of the peptide having a GLP-1 activity. These derivatives are highly absorbable via a mucous membrane. The GLP-1 derivative can be conferred with resistance to dipeptidyl peptidase IV by substituting amino acid 8 in its GLP-1 amino acid sequence with Ser, or with resistance to trypsin by substituting amino acids 26 and 34 with Gln and Asn, respectively.The absorption efficiency of the GLP-1 derivatives via mucous membranes can be further improved by preparing a composition using a charge-regulated fat emulsion regulated to be negatively charged thereon.

REFERENCES:
patent: 6528486 (2003-03-01), Larsen et al.
patent: 6903186 (2005-06-01), Dong
patent: 2003/0199672 (2003-10-01), Knudsen et al.
patent: 2 321 026 (1999-09-01), None
patent: 0 978 565 (2000-02-01), None
patent: 1 076 066 (2001-02-01), None
patent: 1 329 458 (2003-07-01), None
patent: 1996-A-027018 (1996-01-01), None
patent: 2002-509082 (2002-03-01), None
patent: 2002-512175 (2002-04-01), None
patent: 2003-505347 (2003-02-01), None
patent: 99/43706 (1999-09-01), None
patent: 99/46283 (1999-09-01), None
patent: 01/04156 (2001-01-01), None
C.F. Deacon et al., “Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity”, Diabetologia (1998) 41:271-278.
Q. Xiao et al., “Biological Activities of Glucagon-Like Peptide-1 Analogues in Vitro and in Vivo”, Biochemistry 2001, 40: 2860-2869.
C. Mark B. Edwards et al., “Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers”, Am J Physiol Endocrinol Metab, 281: E155-E161, 2001.
Mark K. Gutniak, MD, PHD et al., “GLP-1 Tablet in Type 2 Diabetes in Fasting and Postprandial Conditions”, Diabetes Care, vol. 20, No. 12, Dec. 1997, pps. 1874-1879.

Affiliated with

Also associated with

Rating

GLP-1 derivative and preparation thereof absorbable via... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with GLP-1 derivative and preparation thereof absorbable via..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and GLP-1 derivative and preparation thereof absorbable via... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3813240